Market Overview:
The global pegfilgrastim biosimilar market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for cost-effective therapies, and growing preference for biosimilars over branded drugs. Based on type, the global pegfilgrastim biosimilar market can be segmented into chemotherapy treatment and transplantation. The chemotherapy treatment segment is expected to account for the majority share of the global pegfilgrastim biosimilar market in 2018. This segment is projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. This growth can be attributed to increasing use of chemotherapeutic agents for cancer treatment and rising demand for cost-effective therapies. Based on application, the global pegfilgrastim biosimilar market can be divided into hospital pharmacies, mail-order pharmacies, and retail pharmacies.
Product Definition:
Pegfilgrastim biosimilar is a protein drug made to imitate the action of naturally occurring human granulocyte colony-stimulating factor (G-CSF). Pegfilgrastim biosimilar is used to increase the number of white blood cells in people with cancer or other medical conditions.
Chemotherapy Treatment:
Chemotherapy is a group of medical treatments used to treat cancer. Chemotherapies are drugs and/or radiation therapy used in combination with surgery or alone for the treatment of cancer. The most common types of chemotherapies include alkylating agents, cytotoxic agents, plant derivatives, and antimetabolites.
Transplantation:
Transplantation is a surgical procedure to replace or restore tissue function or structure in the body. It's most commonly used for the replacement of organs damaged by disease, accident, or congenital defects. The most common types of transplant procedures are kidney, liver, heart valve and tissues (such as skin), bone marrow stem cells and cornea.
Application Insights:
Based on application, the market is segmented into hospital pharmacies, mail-order pharmacies, and retail pharmacies. The hospital pharmacy segment dominated the overall market in terms of revenue in 2017. This can be attributed to factors such as a high prevalence of cancer coupled with rising awareness about chemotherapy treatment among patients at hospitals globally. Furthermore, Pegfilgrastim biosimilars are widely used for stem cell transplantation therapy which accounts for a significant share in chemotherapy treatment at hospitals thus boosting demand from this sector.
The Mail-Order Pharmacies (MOP) segment is expected to grow significantly over the forecast period owing to growing adoption of Pegfilgrastim biosimilars by MOPs due to its low cost and convenience compared to conventional chemotherapeutic drugs that are generally available within these stores/pharmacies worldwide.
Regional Analysis:
North America dominated the global market in 2017. Key factors contributing to its growth include favorable reimbursement policies, high healthcare expenditure, and increasing number of FDA approvals. In December 2016, UHG received approval from the FDA for Peg-filgrastim/ pegfilgrastim-tetrahydrochloride combination product (Neupogen) for use by adults with cancer who are undergoing chemotherapy or stem cell transplantation. The product is indicated as a single dose regimen that can be taken up to 3 times per week after consulting with one's doctor.
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to rising healthcare expenditure and improving access due to government initiatives such as National Health Mission 2015–2016.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the pegfilgrastim biosimilar market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for pegfilgrastim biosimilars as they offer an affordable treatment option for patients with this disease.
- Rising geriatric population: The global geriatric population is growing at a rapid pace and this is expected to drive demand for pegfilgrastim biosimilars over the forecast period. As per United Nations estimates, the number of people aged 60 years or above is projected to reach 2 billion by 2050, accounting for nearly one-third of the world’s population. This rising geriatric population is more susceptible to various types of cancers and other life-threatening diseases and would benefit from using pegfilgrastim biosimilars as a cost-effective treatment option..
Scope Of The Report
Report Attributes
Report Details
Report Title
Pegfilgrastim Biosimilar Market Research Report
By Type
Chemotherapy Treatment, Transplantation
By Application
Hospital Pharmacies, Mail-Order Pharmacies, Retail Pharmacies
By Companies
Novartis, Mylan, Coherus BioSciences, Mundipharma International, Biocon, Intas Pharmaceuticals, Pfizer, Dr Reddy’s Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Pegfilgrastim Biosimilar Market Report Segments:
The global Pegfilgrastim Biosimilar market is segmented on the basis of:
Types
Chemotherapy Treatment, Transplantation
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Mail-Order Pharmacies, Retail Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Mylan
- Coherus BioSciences
- Mundipharma International
- Biocon
- Intas Pharmaceuticals
- Pfizer
- Dr Reddy’s Laboratories
Highlights of The Pegfilgrastim Biosimilar Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy Treatment
- Transplantation
- By Application:
- Hospital Pharmacies
- Mail-Order Pharmacies
- Retail Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pegfilgrastim Biosimilar Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pegfilgrastim Biosimilar is a biosimilar drug that is derived from filgrastim, which is a growth factor used to help improve the quality of life for patients with cancer. Pegfilgrastim Biosimilar was developed by Amgen and is approved in Europe and Asia.
Some of the major players in the pegfilgrastim biosimilar market are Novartis, Mylan, Coherus BioSciences, Mundipharma International, Biocon, Intas Pharmaceuticals, Pfizer, Dr Reddy’s Laboratories.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pegfilgrastim Biosimilar Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pegfilgrastim Biosimilar Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pegfilgrastim Biosimilar Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pegfilgrastim Biosimilar Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pegfilgrastim Biosimilar Market Size & Forecast, 2018-2028
4.5.1 Pegfilgrastim Biosimilar Market Size and Y-o-Y Growth
4.5.2 Pegfilgrastim Biosimilar Market Absolute $ Opportunity
Chapter 5 Global Pegfilgrastim Biosimilar Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pegfilgrastim Biosimilar Market Size Forecast by Type
5.2.1 Chemotherapy Treatment
5.2.2 Transplantation
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pegfilgrastim Biosimilar Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pegfilgrastim Biosimilar Market Size Forecast by Applications
6.2.1 Hospital Pharmacies
6.2.2 Mail-Order Pharmacies
6.2.3 Retail Pharmacies
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pegfilgrastim Biosimilar Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pegfilgrastim Biosimilar Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pegfilgrastim Biosimilar Analysis and Forecast
9.1 Introduction
9.2 North America Pegfilgrastim Biosimilar Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pegfilgrastim Biosimilar Market Size Forecast by Type
9.6.1 Chemotherapy Treatment
9.6.2 Transplantation
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pegfilgrastim Biosimilar Market Size Forecast by Applications
9.10.1 Hospital Pharmacies
9.10.2 Mail-Order Pharmacies
9.10.3 Retail Pharmacies
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pegfilgrastim Biosimilar Analysis and Forecast
10.1 Introduction
10.2 Europe Pegfilgrastim Biosimilar Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pegfilgrastim Biosimilar Market Size Forecast by Type
10.6.1 Chemotherapy Treatment
10.6.2 Transplantation
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pegfilgrastim Biosimilar Market Size Forecast by Applications
10.10.1 Hospital Pharmacies
10.10.2 Mail-Order Pharmacies
10.10.3 Retail Pharmacies
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pegfilgrastim Biosimilar Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pegfilgrastim Biosimilar Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pegfilgrastim Biosimilar Market Size Forecast by Type
11.6.1 Chemotherapy Treatment
11.6.2 Transplantation
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pegfilgrastim Biosimilar Market Size Forecast by Applications
11.10.1 Hospital Pharmacies
11.10.2 Mail-Order Pharmacies
11.10.3 Retail Pharmacies
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pegfilgrastim Biosimilar Analysis and Forecast
12.1 Introduction
12.2 Latin America Pegfilgrastim Biosimilar Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pegfilgrastim Biosimilar Market Size Forecast by Type
12.6.1 Chemotherapy Treatment
12.6.2 Transplantation
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pegfilgrastim Biosimilar Market Size Forecast by Applications
12.10.1 Hospital Pharmacies
12.10.2 Mail-Order Pharmacies
12.10.3 Retail Pharmacies
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pegfilgrastim Biosimilar Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pegfilgrastim Biosimilar Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pegfilgrastim Biosimilar Market Size Forecast by Type
13.6.1 Chemotherapy Treatment
13.6.2 Transplantation
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pegfilgrastim Biosimilar Market Size Forecast by Applications
13.10.1 Hospital Pharmacies
13.10.2 Mail-Order Pharmacies
13.10.3 Retail Pharmacies
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pegfilgrastim Biosimilar Market: Competitive Dashboard
14.2 Global Pegfilgrastim Biosimilar Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novartis
14.3.2 Mylan
14.3.3 Coherus BioSciences
14.3.4 Mundipharma International
14.3.5 Biocon
14.3.6 Intas Pharmaceuticals
14.3.7 Pfizer
14.3.8 Dr Reddy’s Laboratories
